학술논문
국소 진행된 두경부암의 병합요법
이용수 4
- 영문명
- Combined Modality Treatment in Head and Neck Cancer
- 발행기관
- 대한두경부종양학회
- 저자명
- 박인규(In Kyu Park) 이호준(Ho Jun Lee) 윤상모(Sang Mo Yun) 김재철(Jae Chul Kim)
- 간행물 정보
- 『대한두경부종양학회지』제17권 제1호, 32~37쪽, 전체 6쪽
- 주제분류
- 의약학 > 종양학
- 파일형태
- 발행일자
- 2001.05.30
4,000원
구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.
국문 초록
영문 초록
Objectives: We performed this study to compare the short term results of induction chemotherapy and radiotherapy versus concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Materials and Methods: From Oct. 1985 to May 1998, 121 patients with locally advanced head and neck cancer were treated with induction chemotherapy and radiotherapy (induction group) or concurrent chemoradiotherapy (concurrent group), and a retrospective analysis was done. Induction chemotherapy was done for 97 patients, and concurrent chemotherapy for 24 patients. Age, sex, performance status, and pathologic types were evenly distributed between two groups. Primary site showed nasopharynx(72.2%), oropharynx(27.8%) in induction group, and nasopharynx(50%), oropharynx(50%) in concurrent group. Chemotherapy regimen was CF(cisplatin and 5-fluorouracil) for 67 patients and CVB (cisplatin, vincristine, bleomycin) for 30 patients in induction group, and CF for all of 24 patients in concurrent group. Proportion of patients treated with more than 2 cycles of planned chemotherapy was 94.8% in induction group and 87.5% in concurrent group. Conventionally fractionated radiotherapy with daily fraction size of 1.8-2.0Gy and 5 fractions/week was done. Total dose was 61-95Gy (median 73.4Gy) for induction group, and 69.4-75.4Gy (median 69.4Gy) for concurrent group. Follow-up time was 4-161 months (median 38 months) for induction group, 7-35 months (median 21.5 months) for concurrent group, respectively.
Results: According to treatment modality, overall 2-year survival rates were 68.0% for induction group, 74.3% for concurrent group (p>0.05). two-year disease-free survival rates were 51 % and 74% (p=0.05). Complete response rates were 67.4% for induction group and 83.3% for concurrent group (p=0.09). The incidence of grade 3-4 hematologic toxicity (2.1% vs. 25%, p=0.001) and grade 3-4 mucositis (9.3% vs. 37.5%, p=0.002) during radiotherapy was higher in concurrent group.
Conclusion: Concurrent chemoradiotherapy showed a trend of improvement in short-term survival and treatment response when compared with induction chemotherapy and radiotherapy in locally advanced head and neck cancer. A more controlled randomized trial is needed.
목차
Abstract
서론
재료 및 방법
결과
고찰 및 결론
References
키워드
해당간행물 수록 논문
- 이하선 종괴로 발현된 악성 림프종
- 인체 편평상피세포암세포주에서 9-Hydroxypheophorbide-α와 660nm Diode 레이저를 이용한 광역학치료의 항암효과
- 방사선치료 조사영역 내에 발생한 설암 환자에서 입체조형방사선치료 경험
- 진행된 경부 전이암에서 경동맥 절제를 위한 술전검사와 절제술의 의의
- 국소 진행된 두경부암의 병합요법
- 갑상선엽절제 후 이차 근치엽절제술을 시행받은 분화성 갑상선암종 환자 23예에 대한 임상적 평가
- 갑상선 기능항진증이 동반된 미분화 갑상선암 1예
- 서로 다른 분엽에 동시에 발생한 유두성과 여포성 갑상선암
- 경부청소술 시료의 기록과 자료의 보관
- A Case of Sclerosing Mucoepidermoid Thyroid Carcinoma with Eosinophilia (SMECE)
- 색채 및 펄스 도플러 초음파를 이용한 경부 림프절의 양성과 악성의 감별
- 자연 관해된 하수체 졸중 1례
- 갑상선 결절의 진단에서 초음파의 유용성
참고문헌
관련논문
의약학 > 종양학분야 BEST
- 방사선 치료에 내성이 유도된 두경부 편평세포암에 대한 종양살상 헤르페스 바이러스의 유전자 치료 효과
- 식도암에서 근치적 절제술 후 방사선치료의 역할
- 두경부암에서 면역회피 기전과 면역항암제 치료
의약학 > 종양학분야 NEW
- Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study
- Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck
- Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy
최근 이용한 논문
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!